BBR Partners’s LENZ Therapeutics LENZ Stock Holding History

BBR Partners’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40,000	Closed	-$1.03M	–	268
2025 Q1	$1.03M	Hold	40,000	–	–	0.07%	95
2024 Q4	$1.15M	Hold	40,000	–	–	0.08%	90
2024 Q3	$950K	Buy	40,000 +20,000	+100%	+$444K	0.07%	89
2024 Q2	$346K	Buy	+20,000	New	+$349K	0.03%	147
2024 Q1	–	Sell	-5,246	Closed	-$96.2K	–	261
2023 Q4	$96.2K	Hold	5,246	–	–	0.01%	183
2023 Q3	$91.1K	Buy	+5,246	New	+$91.2K	0.01%	189

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BBR Partners's LENZ Position: Q2 2025 in Review

BBR Partners sold out of LENZ Therapeutics (LENZ) in Q2 2025, closing a stake of 40,000 shares — an estimated $1.03M sold.

BBR Partners first reported a position in LENZ in Q3 2023 and held it in 6 quarters. The position peaked at $1.15M in Q4 2024. 113 funds tracked by Wall St. Rank hold LENZ as of Q2 2025.

BBR Partners reported no remaining LENZ Therapeutics position as of Q2 2025 after selling out during the quarter.
BBR Partners sold 40,000 LENZ Therapeutics shares in Q2 2025, an estimated $1.03M.
BBR Partners first reported a position in LENZ Therapeutics in Q3 2023 and held it in 6 quarters.
BBR Partners's LENZ Therapeutics position peaked at $1.15M in Q4 2024.
113 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2025.

Based on BBR Partners's 13F filing for Q2 2025, filed 14 Aug 2025.